767 related articles for article (PubMed ID: 24094812)
1. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Timmerman LA; Holton T; Yuneva M; Louie RJ; Padró M; Daemen A; Hu M; Chan DA; Ethier SP; van 't Veer LJ; Polyak K; McCormick F; Gray JW
Cancer Cell; 2013 Oct; 24(4):450-65. PubMed ID: 24094812
[TBL] [Abstract][Full Text] [Related]
2. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.
Wang F; Yang Y
Breast Cancer Res Treat; 2014 Aug; 147(1):203-10. PubMed ID: 25085754
[TBL] [Abstract][Full Text] [Related]
3. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
4. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
[TBL] [Abstract][Full Text] [Related]
5. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
[TBL] [Abstract][Full Text] [Related]
6. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
[TBL] [Abstract][Full Text] [Related]
7. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
Shin CS; Mishra P; Watrous JD; Carelli V; D'Aurelio M; Jain M; Chan DC
Nat Commun; 2017 Apr; 8():15074. PubMed ID: 28429737
[TBL] [Abstract][Full Text] [Related]
8. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.
Ji X; Qian J; Rahman SMJ; Siska PJ; Zou Y; Harris BK; Hoeksema MD; Trenary IA; Heidi C; Eisenberg R; Rathmell JC; Young JD; Massion PP
Oncogene; 2018 Sep; 37(36):5007-5019. PubMed ID: 29789716
[TBL] [Abstract][Full Text] [Related]
9. Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury.
Meyer AR; Engevik AC; Willet SG; Williams JA; Zou Y; Massion PP; Mills JC; Choi E; Goldenring JR
Cell Mol Gastroenterol Hepatol; 2019; 8(3):379-405. PubMed ID: 31071489
[TBL] [Abstract][Full Text] [Related]
10. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
11. xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain.
Ungard RG; Linher-Melville K; Nashed MG; Sharma M; Wen J; Singh G
Mol Pain; 2019; 15():1744806918822185. PubMed ID: 30799686
[TBL] [Abstract][Full Text] [Related]
12. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.
Habib E; Linher-Melville K; Lin HX; Singh G
Redox Biol; 2015 Aug; 5():33-42. PubMed ID: 25827424
[TBL] [Abstract][Full Text] [Related]
13.
Yang H; Jenni S; Colovic M; Merkens H; Poleschuk C; Rodrigo I; Miao Q; Johnson BF; Rishel MJ; Sossi V; Webster JM; Bénard F; Schaffer P
J Nucl Med; 2017 Mar; 58(3):367-373. PubMed ID: 27789715
[TBL] [Abstract][Full Text] [Related]
14. Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.
Ye P; Mimura J; Okada T; Sato H; Liu T; Maruyama A; Ohyama C; Itoh K
Mol Cell Biol; 2014 Sep; 34(18):3421-34. PubMed ID: 25002527
[TBL] [Abstract][Full Text] [Related]
15. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
Koppula P; Zhuang L; Gan B
Protein Cell; 2021 Aug; 12(8):599-620. PubMed ID: 33000412
[TBL] [Abstract][Full Text] [Related]
16. IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-.
Yang Y; Yee D
Cancer Res; 2014 Apr; 74(8):2295-305. PubMed ID: 24686172
[TBL] [Abstract][Full Text] [Related]
17. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
[TBL] [Abstract][Full Text] [Related]
18. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway.
Chen RS; Song YM; Zhou ZY; Tong T; Li Y; Fu M; Guo XL; Dong LJ; He X; Qiao HX; Zhan QM; Li W
Oncogene; 2009 Jan; 28(4):599-609. PubMed ID: 19015640
[TBL] [Abstract][Full Text] [Related]
19. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
20. Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer.
Sendo K; Seino M; Ohta T; Nagase S
Oncotarget; 2022; 13():224-236. PubMed ID: 35106124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
